68 results
8-K
EX-10.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
on representations made by Remainco, Spinco, Parent, and their respective representatives, and not by independent review, and shall function only as an expert
425
7nuuqgxv
24 Mar 22
Business combination disclosure
9:09am
8-K
EX-2.1
l3117vgvrpbgy
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-99.1
i8nkgmktctayo9
29 Jul 21
Ligand Reports Second Quarter 2021 Financial Results
4:04pm
8-K
EX-2.1
oao3j g49q2gi3jlk1ju
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
EX-10.4
hl539g 60yz6
10 Sep 20
Entry into a Material Definitive Agreement
4:43pm